Wednesday, GSK Plc (NYSE:GSK) reported fourth-quarter adjusted operating profit of £1.75 billion, up 10% at the actual exchange rate (AER) and up 21% at the constant exchange rate (CER). The company’s RSV vaccine, Arexvy, hit £1.2 billion in sales in 2023 and £529 million in the fourth quarter. Approximately 6 million of the 83 million U.S. adults aged 60 and older at risk have been vaccinated with Arexvy. The company reported sales of $10 billion (£8.1 billion), beating the consensus of $9.61 billion. Also Read:GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Ov…
